Patents by Inventor Alexander Riedel

Alexander Riedel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11404152
    Abstract: A data collection device is configured to capture images of a dosage indicator of a medicament delivery device and, if an injection is administered without prior confirmation of a dosage amount, to prompt the user to set a value for the delivered medicament dosage amount for storing in a dosage log. For example, the determination may be based on specific confirmation from the user or detecting a zero dosage amount in captured images. A suggested dosage amount may be displayed to the user, for example a highest or more recently programmed dosage amount prior to the injection or based on one or more previously confirmed dosage amounts. The data collection device may use one or more of optical character recognition, optical pattern recognition and determination of direction of rotation of a dosage adjustment component to determine whether an injection is being, or has been, administered and/or a suggested dosage amount.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: August 2, 2022
    Assignee: Sanofi-Aventis Deutschland GMBH
    Inventors: Stephan Riedel, Isabel Klein, Alexander Allerdings, Christian Nessel
  • Publication number: 20220220158
    Abstract: The disclosure relates to a polypeptide suitable for detecting antibodies against a flavivirus in an isolated biological sample having a flavivirus NS1 wing domain specific amino acid sequence, wherein no amino acid sequences from the NS1 ?-ladder domain of said flavivirus are present in the polypeptide. In an embodiment, the flavivirus is selected from Zika virus (ZIKV), West-Nile virus (WNV), Dengue virus types 1-4 (DENV1-4), tick-borne encephalitis virus (TBEV), yellow fever virus (YFV) and Japanese encephalitis virus (JEV). Also disclosed is a method for producing said flaviviral NS1 wing domain specific polypeptides, a method for detecting antibodies specific for a first flavivirus species, the use of said flaviviral NS1 wing domain specific polypeptides for detecting antibodies as well as a reagent kit for detecting said flavivirus antibodies that has a flavivirus NS1 wing domain polypeptide.
    Type: Application
    Filed: March 28, 2022
    Publication date: July 14, 2022
    Inventors: Elke Faatz, Alexander Riedel, Christian Scholz, Peter Muench, Gloria Tabares, Mario Gloeck, Silke Luebcke, Juliane Benz
  • Patent number: 11319351
    Abstract: The disclosure relates to a polypeptide suitable for detecting antibodies against a flavivirus in an isolated biological sample having a flavivirus NS1 wing domain specific amino acid sequence, wherein no amino acid sequences from the NS1 ß-ladder domain of said flavivirus are present in the polypeptide. In an embodiment, the flavivirus is selected from Zika virus (ZIKV), West-Nile virus (WNV), Dengue virus types 1-4 (DENV1-4), tick-borne encephalitis virus (TBEV), yellow fever virus (YFV) and Japanese encephalitis virus (JEV). Also disclosed is a method for producing said flaviviral NS1 wing domain specific polypeptides, a method for detecting antibodies specific for a first flavivirus species, the use of said flaviviral NS1 wing domain specific polypeptides for detecting antibodies as well as a reagent kit for detecting said flavivirus antibodies that has a flavivirus NS1 wing domain polypeptide.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: May 3, 2022
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Elke Faatz, Alexander Riedel, Christian Scholz, Peter Muench, Gloria Tabares, Mario Gloeck, Silke Luebcke, Juliane Benz
  • Patent number: 11312750
    Abstract: The disclosure concerns a polypeptide suitable for detecting antibodies against Zika virus in an isolated biological sample having a Zika virus NS1 wing domain specific amino acid sequence and variants thereof, wherein no further Zika virus specific amino acid sequences are present in the polypeptide. This polypeptide does not immunologically cross-react with antibodies raised against structurally related antigens from tick-borne encephalitis virus, Dengue virus 1-4, West Nile virus, yellow fever virus or Japanese encephalitis virus, but immunologically reacts with antibodies raised against full length Zika virus NS1 antigen. Also disclosed is a method of producing a soluble and immunoreactive Zika virus NS1 polypeptide as well as methods and kits for detecting antibodies specific for Zika virus in an isolated sample.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: April 26, 2022
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Elke Faatz, Mario Gloeck, Peter Muench, Alexander Riedel, Christian Scholz, Gloria Tabares
  • Publication number: 20210349090
    Abstract: The present description relates to a Corona antigen having a Corona nucleocapsid specific amino acid sequence, compositions, and reagent kits having the same and methods of producing it. Also encompassed are methods of detecting anti-Corona antibodies in samples using the Corona antigen, and methods of differential diagnosis of an immune response in a patient due to natural Corona infection or due to vaccination against Corona.
    Type: Application
    Filed: May 6, 2020
    Publication date: November 11, 2021
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Alexander Riedel, Christian Scholz, Peter Muench, Juliane Benz, Markus Eckl, Frederik Baumkoetter
  • Publication number: 20210333277
    Abstract: The present invention relates to a Corona antigen comprising a Corona nucleocapsid specific amino acid sequence, compositions, and reagent kits comprising the same and methods of producing it. Also encompassed are methods of detecting anti-Corona antibodies in samples using said Corona antigen, and methods of differential diagnosis of an immune response in a patient due to natural Corona infection or due to vaccination against Corona.
    Type: Application
    Filed: April 23, 2020
    Publication date: October 28, 2021
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Alexander Riedel, Christian Scholz, Peter Muench, Juliane Benz, Markus Eckl, Frederik Baumkoetter
  • Publication number: 20200048313
    Abstract: The disclosure relates to a polypeptide suitable for detecting antibodies against a flavivirus in an isolated biological sample having a flavivirus NS1 wing domain specific amino acid sequence, wherein no amino acid sequences from the NS1 ß-ladder domain of said flavivirus are present in the polypeptide. In an embodiment, the flavivirus is selected from Zika virus (ZIKV), West-Nile virus (WNV), Dengue virus types 1-4 (DENV1-4), tick-borne encephalitis virus (TBEV), yellow fever virus (YFV) and Japanese encephalitis virus (JEV). Also disclosed is a method for producing said flaviviral NS1 wing domain specific polypeptides, a method for detecting antibodies specific for a first flavivirus species, the use of said flaviviral NS1 wing domain specific polypeptides for detecting antibodies as well as a reagent kit for detecting said flavivirus antibodies that has a flavivirus NS1 wing domain polypeptide.
    Type: Application
    Filed: October 25, 2019
    Publication date: February 13, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Elke Faatz, Alexander Riedel, Christian Scholz, Peter Muench, Gloria Tabares, Mario Gloeck, Silke Luebcke, Juliane Benz
  • Publication number: 20200048312
    Abstract: The disclosure concerns a polypeptide suitable for detecting antibodies against Zika virus in an isolated biological sample having a Zika virus NS1 wing domain specific amino acid sequence and variants thereof, wherein no further Zika virus specific amino acid sequences are present in the polypeptide. This polypeptide does not immunologically cross-react with antibodies raised against structurally related antigens from tick-borne encephalitis virus, Dengue virus 1-4, West Nile virus, yellow fever virus or Japanese encephalitis virus, but immunologically reacts with antibodies raised against full length Zika virus NS1 antigen. Also disclosed is a method of producing a soluble and immunoreactive Zika virus NS1 polypeptide as well as methods and kits for detecting antibodies specific for Zika virus in an isolated sample.
    Type: Application
    Filed: October 25, 2019
    Publication date: February 13, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Elke Faatz, Mario Gloeck, Peter Muench, Alexander Riedel, Christian Scholz, Gloria Tabares
  • Patent number: 10197559
    Abstract: The invention concerns a fusion polypeptide including several molecules of folding helper polypeptides, including one multimerization domain, in particular Skp, and at least one molecule of SlyD or SlpA, wherein no further target polypeptide sequences are fused to the fusion polypeptide. The invention further concerns an immunoassay and the use of the fusion polypeptide in an immunoassay for reduction of interferences or minimizing false positive results or for stabilizing proteinaceous assay reagents. Further the invention concerns a reagent kit for use in an immunoassay comprising the fusion polypeptide.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: February 5, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Hartmut Duefel, Alexander Riedel, Peter Schaarschmidt, Urban Schmitt, Christian Scholz
  • Publication number: 20170261498
    Abstract: The invention concerns a fusion polypeptide comprising several molecules of folding helper polypeptides, comprising one multimerization domain, in particular Skp, and at least one molecule of SlyD or SlpA, wherein no further target polypeptide sequences are fused to said fusion polypeptide. The invention further concerns an immunoassay and the use of said fusion polypeptide in an immunoassay for reduction of interferences or minimizing false positive results or for stabilizing proteinaceous assay reagents. Further the invention concerns a reagent kit for use in an immunoassay comprising said fusion polypeptide.
    Type: Application
    Filed: March 6, 2015
    Publication date: September 14, 2017
    Inventors: Hartmut Duefel, Alexander Riedel, Peter Schaarschmidt, Urban Schmitt, Christian Scholz